To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease and Death in Diabetic Nephropathy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00120328|
Recruitment Status : Terminated
First Posted : July 15, 2005
Last Update Posted : October 5, 2007
|Condition or disease||Intervention/treatment||Phase|
|Diabetic Nephropathy||Drug: SPP301||Phase 3|
Diabetic nephropathy has become the leading cause of end stage renal disease (ESRD) in the western world, accounting for approximately 40% of new cases in the US, and up to 20 to 30% in Europe.
Current treatments for diabetic nephropathy usually try to deal with the underlying diabetes or they aim to reduce cardiovascular risk factors such as hypertension, hyperglycemia, smoking and dyslipidemia. A few recently approved drugs such as irbesartan and losartan (for type 2 diabetic nephropathy) have a renoprotective activity beyond their antihypertensive effect. However, morbidity and mortality rates remain high.
Avosentan may have a positive effect on reducing the amount of protein lost in the urine and if this is the case it will help treat patients with diabetic nephropathy.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||2364 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||ASCEND - A Randomised, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Effect of the Endothelin Receptor Antagonist Avosentan on Time to Doubling of Serum Creatinine, End Stage Renal Disease or Death in Patients With Type 2 Diabetes Mellitus and Diabetic Nephropathy|
|Study Start Date :||July 2005|
|Actual Study Completion Date :||February 2007|
- To determine the effect of each dose of avosentan on time to doubling of serum creatinine, end stage renal disease (ESRD) or death when administered on top of standard treatment in subjects with type 2 diabetes mellitus and diabetic nephropathy.
- To determine the effect of each dose of avosentan on: cardiovascular mortality
- non-cardiovascular mortality
- coronary or peripheral vascular revascularisations including amputations (except where due to trauma)
- non-fatal acute myocardial infarction
- congestive heart failure
- unstable angina
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00120328
|United States, North Carolina|
|Dr. Mark Warren|
|Greenville, North Carolina, United States, 27834|
|Study Director:||Jessica Mann, MD, PhD||Speedel Pharma Ltd.|